RT Journal Article
SR Electronic
T1 Flexible and Highly-Efficient Feature Perception for Molecular Traits Prediction via Self-interactive Deep Learning
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.07.30.23293391
DO 10.1101/2023.07.30.23293391
A1 Hu, Yang
A1 Sirinukunwattana, Korsuk
A1 Li, Bin
A1 Gaitskell, Kezia
A1 Bonnaffé, Willem
A1 Wojciechowska, Marta
A1 Wood, Ruby
A1 Alham, Nasullah Khalid
A1 Malacrino, Stefano
A1 Woodcock, Dan
A1 Verrill, Clare
A1 Ahmed, Ahmed
A1 Rittscher, Jens
YR 2023
UL http://medrxiv.org/content/early/2023/08/05/2023.07.30.23293391.abstract
AB Predicting disease-related molecular traits from histomorphology brings great opportunities for precision medicine. Despite the rich information present in histopathological images, extracting fine-grained molecular features from standard whole slide images (WSI) is non-trivial. The task is further complicated by the lack of annotations for subtyping and contextual histomorphological features that might span multiple scales. This work proposes a novel multiple-instance learning (MIL) framework capable of WSI-based cancer morpho-molecular subtyping across scales. Our method, debuting as Inter-MIL, follows a weakly-supervised scheme. It enables the training of the patch-level encoder for WSI in a task-aware optimisation procedure, a step normally improbable in most existing MIL-based WSI analysis frameworks. We demonstrate that optimising the patch-level encoder is crucial to achieving high-quality fine-grained and tissue-level subtyping results and offers a significant improvement over task-agnostic encoders. Our approach deploys a pseudo-label propagation strategy to update the patch encoder iteratively, allowing discriminative subtype features to be learned. This mechanism also empowers extracting fine-grained attention within image tiles (the small patches), a task largely ignored in most existing weakly supervised-based frameworks. With Inter-MIL, we carried out four challenging cancer molecular subtyping tasks in the context of ovarian, colorectal, lung, and breast cancer. Extensive evaluation results show that Inter-MIL is a robust framework for cancer morpho-molecular subtyping with superior performance compared to several recently proposed methods, even in data-limited scenarios where the number of available training slides is less than 100. The iterative optimisation mechanism of Inter-MIL significantly improves the quality of the image features learned by the patch embedded and generally directs the attention map to areas that better align with experts’ interpretation, leading to the identification of more reliable histopathology biomarkers.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by: Y.H., C.V. and J.R. National Institute for Health Research (NIHR) Oxford Biomedical Research Centre; K.S., C.V., and J.R. Innovate UK funded PathLAKE consortium; K.G. Clinical Lectureship from the National Institute for Health Research (NIHR, grant no. CL-2017-13-001); R.W. EPSRC Centre for Doctoral Training in Health Data Science (EP/S02428X/1) and Oxford CRUK Centre for Cancer Research. Computation used the Oxford Biomedical Research Computing (BMRC) facility.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.